Showing 76–100 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Gunar Günther, Lorenzo Guglielmetti, Claude Leu, Christoph Lange, Frank van Leth, et al.
…berculosis drugs and calculated cost of drugs and treatment regimens at major tuberculosis treatment centers in countries of the World Health Organization (WHO) European region. Results are stratified by middle and high-income countries. Results Overall, 43 treatment centers in 4…
J. A. M. Raaijmakers, Sandra Salillas, Rob E. Aarnoutse, Elin M. Svensson, Lindsey te Brake, et al.
…macodynamics were monitored throughout the experiment. Both regimens led to sustained bacterial killing (both intracellular and extracellular) throughout the experiment. No difference in kill rate was observed between the two therapies. The extracellular kill rate for the 3-drug …
Dhondiba Haribhau Bhise
…tum smear conversion in daily versus intermittent treatment regimens in diagnosed cases of new sputum smear-positive pulmonary tuberculosis patients. METHODS This retrospective observational study was carried out in the Department of Respiratory medicine and nodal drug resistance…
Banurekha Velayutham, M S Jawahar, Chandrasekaran Padmapriyadarsini
…ence to our paper entitled ‘4-month moxifloxacin containing regimens in the treatment of patients with sputum-positive pulmonary tuberculosis in South India – a randomised clinical trial’ in the letter ‘False equivalence of four month and six-month ATT regimen: A case of comparin…
Oki Nugraha Putra, Ana Khusnul Faizah, Nani Wijayanti Dyah Nurrahman
…eatment failure, and loss of follow-up) related to all oral regimens containing bedaquiline and or delamanid in patients with MDR-TB. Method: This was a narrative review to summarize the role of the BPaL regimen to manage highly DR-TB patients. Results: The six months of BPaL reg…
Zarir Udwadia, Jennifer Furin
…n it comes to rolling out bedaquiline (BDQ)-based, all-oral regimens for drug-resistant forms of tuberculosis (DR-TB). India is home to the largest population of people living with DR-TB in the world,[2] and improving access to innovative diagnostic and therapeutic approaches is …
Hua Li, Tong Li, Jun Wang, Qingtao Liang, Yun Zhang, et al.
BACKGROUND: ) lung disease remains far from satisfying. An effective regimen is needed to solve the problem. METHODS: lung disease who received antibiotics regimen at Beijing Chest Hospital Affiliated to Capital Medical University between July 1, 2010, and February 1, 2018. Patie…
Rashmi Ratnam, Roli Kushwaha, Parul Jain, Amita Jain
…tuberculosis (DR-TB), introduced two bedaquiline-containing regimens endorsed by the WHO for Rifampicin-resistant/Multi-drug resistant tuberculosis (RR/MDR TB). This study assesses clinical and microbiological outcomes of these regimens in RR/MDR TB patients. <bold>Material & Met…
Е. А. Бородулина, М.В. Ураксина, E. P. Еremenko, T. M. Larionova, A. N. Gerasimov
…tment method seems relevant. Aim: To analyze the prescribed regimens and the reason for their correction in newly identified patients before verifying the diagnosis of tuberculosis. Material and Methods. The following methods were used to detect MBT: luminescent microscopy, molec…
Vijay Kumar, Upinder Kaur, Mohit Bhatia, Jaya Mishra
<bold>Introduction:</bold> Real-world evidence on oral regimens for drug-resistant tuberculosis (DR-TB) is scarce. <bold>Aims and objectives:</bold> To assess culture conversion at 6 months and adverse events (AEs) with oral regimens of DR-TB. <bold>Methods:</bold> A prospective …
Bern-Thomas Nyang'wa, MD
… controlled, phase II-III trial; evaluating short treatment regimens containing bedaquiline and pretomanid in combination with existing and re-purposed anti-TB drugs for the treatment of biologically confirmed pulmonary multi drug-resistant TB (MDR-TB). This is a multi-centre, o…
Shuang Wei, M.D.
… is an urgent need for new, effective and safe short-course regimens for drug-resistant tuberculosis. A 6-month short-course oral regimen containing pretomanid was introduced in 2020. However, as pretomanid is not yet available in China, it has not been verified and promoted in C…
Wenhong Zhang, Dr.
This study is a randomized controlled trial among asymptomatic tuberculosis individuals aiming to assess whether the standard treatment duration can be shortened to 17 weeks without increasing the types or doses of anti-tuberculosis medications or 13 weeks with the high-dose rifa…
Padmapriyadarsini Chandrasekharan
Existing problem with DR TB management: Injectable regimens for longer duration with toxicity Poor adherence, treatment failures, continued transmission Need of the study: Oral regimens of shorter duration Improved treatment adherence Implementation of community-based models o…
Rokeya Tasneen, Andrew Garcia, Paul J. Converse, Matthew Zimmerman, Véronique Dartois, et al.
…rine models of tuberculosis were used to test whether novel regimens replacing rifapentine and isoniazid with bedaquiline and another drug would maintain or increase the sterilizing activity of the regimen. In BALB/c mice, replacing rifapentine in the PZM backbone with bedaquilin…
Alexander Berg, James Clary, Debra Hanna, Eric L. Nuermberger, Anne J. Lenaerts, et al.
…necessitating the development of new and improved treatment regimens. Non-clinical evaluation of candidate drug combinations via the relapsing mouse model (RMM) is an important step in regimen development, through which candidate regimens that provide the greatest decrease in pro…
Rivaldo Heru Setiawan
…) contributing substantially to poor outcomes. Conventional regimens span 18–24 months, leading to limited adherence and treatment success. Shorter treatment regimens (STRs), such as the BPaL regimen (bedaquiline, pretomanid, and linezolid), have emerged as promising alternatives…
Ajay Gupta
…torically required long, toxic, and operationally demanding regimens–often extending beyond 18 months and associated with treatment fatigue, high default rates, and severe adverse effects. Against this background, the World Health Organization recommended the all-oral, 6-month BP…
Malaisamy Muniyandi, Nagarajan Karikalan, Banurekha Velayutham, Kavitha Rajsekar, Chandrasekaran Padmapriyadarsini
Abstract Globally efforts are underway to shorten the existing 6-month tuberculosis (TB) treatment regimen for drug-sensitive patients, which would be equally effective and safe. At present, there is a lack of evidence on the cost implications of a shorter 4-month TB regimen in I…
David Branigan, Claudia M. Denkinger, Jennifer Furin, Petra Heitkamp, Stijn Deborggraeve, et al.
…s to implement the shortest and best available tuberculosis regimens—1 month or once-weekly for tuberculosis prevention, 4 months for drug-sensitive tuberculosis, and 6 months for drug-resistant tuberculosis—by the end of 2024.1McKenna L Frick M Angami K et al.The 1/4/6x24 campai…
Josephine G R Simanjuntak, Made A K Gandhy, Kynthia Sadha
…y in high- burden regions like Indonesia. Shorter treatment regimens have been proposed to improve outcomes for multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB). This systematic review and Bayesian network meta-analysis aimed to evaluate the efficacy and safety of the…
Chin-Chung Shu
…emains unclear. Currently, three-month rifamycin-containing regimens, such as weekly rifapentine and isoniazid (3HP) or daily rifampicin and isoniazid (3HP), are common because its non-inferiority to nine-month of daily isoniazid (9H) and high completion rate by its short course …
Sha wei
…e public health burden.Research on optimal drug combination regimens to further shorten the duration and improve the efficacy of multidrug-resistant tuberculosis treatment is an important research direction.The PRS (parabolic response surface, FSC.II) system is an enhanced use of…
Stephanie Palacios, Glenford Refre, Patricio Palmes, Ma. Cecilia Momville
…abases, comparing the 4-month and 6-month anti-TB treatment regimens. RCTs that were published in the English language from 2017-2022 that used drug susceptible TB adult patients were included in the final meta-analysis. We compared the efficacy and safety of the two regimens usi…
Jyoti Bajpai, Darshan Kumar Bajaj, Sandeep Kumar, Rashmi Kushwaha, Surya Kant, et al.
…fication test)&LPA(Line Probe Assay)and availability of regimens with duration of 9-11months in contrast to previous lengthy regimens things have become better. Present study was undertaken to study microbiological conversion and adverse effect profile of shorter regimen <b>M…